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Abstract
Introduction: Colorectal cancer is a common malignancy. Identification of genetic prognostic markers may help prognostic
estimations in colorectal cancer. Genes that regulate response to hypoxia and other genes that are regulated under the
hypoxic conditions have been shown to play roles in cancer progression. In this study, we hypothesized that genetic
variations in the hypoxia pathway genes were associated with the risk of outcome in colorectal cancer patients.
Methods: This study was performed in two phases. In the first phase, 49 SNPs from six hypoxia pathway genes (HIF1A, HIF1B,
HIF2A, LOX, MIF and CXCL12) in 272 colorectal cancer patients were analyzed. In the second phase, 77 SNPs from seven
hypoxia pathway genes (HIF1A, HIF1B, HIF2A, HIF2B, HIF3A, LOX and CXCL12) were analyzed in an additional cohort of 535
patients. Kaplan Meier, Cox univariate and multivariable regression analyses were performed to analyze the relationship
between the SNPs and overall survival (OS), disease free survival (DFS) or disease specific survival (DSS). Since this was a
hypothesis-generating study, no correction for multiple testing was applied.
Results: In phase I, one SNP (HIF2A rs11125070) was found to be associated with DFS in multivariable analysis; yet
association of a proxy polymorphism (HIF2A rs4953342) was not detected in the phase II patient cohort. In phase II,
associations of two SNPs (HIF2A rs4953352 and HIF2B rs12593988) were significant in both OS and DFS multivariable
analyses. However, association of HIF2A rs4953352 was not replicated in the phase I cohort using a proxy SNP (HIF2A
rs6706003).
Conclusion: Overall, our study did not find a convincing evidence of association of the investigated polymorphisms with the
disease outcomes in colorectal cancer.
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Introduction
Hypoxia is a condition characterised by low oxygen levels. Solid
tumour cells may experience hypoxic conditions due to restricted
blood flow. While this may cause reduced cell proliferation or
death, sometime it also helps cells adapt to hypoxic conditions by
altering their energy metabolism from oxidative phosphorylation
pathway to glycolysis pathway. Such alterations influence the
expression of hypoxia-inducible genes and treatment outcome in
cancer patients. In addition, hypoxic conditions have been
implicated to promote DNA replication, angiogenesis, and tumor
invasion and metastatic potential. All of these changes facilitate
tumor progression and may negatively affect the patient outcome.
These and other roles of hypoxic conditions in tumor progression
and outcome have been extensively reviewed by many in literature
(for example, [1,2]).
Under hypoxic conditions, cells activate specific molecular
machineries by up-regulating or down-regulating the expression of
certain genes. This is facilitated by the hypoxia inducible factors
(HIFs). HIFs are heterodimeric transcription factors consisting of a
and b subunits. In humans, there are three HIF-a (HIF-1a, HIF-
2a and HIF-3a) and two HIF-b (HIF-1b and HIF-2b). Each of
these subunits is coded by distinct genes (HIF1A, ARNT/HIF1B,
EPAS1/HIF2A, ARNT2/HIF2B, and HIF3A). HIFs bind to
hypoxia responsive elements (HREs) along the hypoxia-regulated
genes to regulate their expression. These hypoxia-inducible genes
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include genes functioning in cell growth, metabolism, DNA
damage response, angiogenesis, and metastasis (reviewed in
[2,3]). Moreover, HIFs also activate genes functioning in cellular
mechanisms that lead resistance to conventional anti-cancer
therapies (reviewed in [3]).
Among the genes regulated by the HIFs are the lysyl oxidase
(LOX) [4], macrophage migration inhibitory factor (MIF) [5] and
C-X-C motif chemokine 12 (CXCL12) [6]. LOX codes for an
enzyme that helps maintain the structural integrity of the
connective tissue and has been identified as a critical driver of
the hypoxia-induced metastasis in human breast tumors [7]. MIF
is known predominantly as an immune system protein, yet in colon
cancer cell lines it promotes hypoxia-driven apoptosis [8].
CXCL12 is another protein mostly known for its role in the
immune system, however it has been shown to influence the tumor
cell death and reduce the metastasis risk in colorectal tumor cell
lines [9].
Colorectal cancer is a common cancer in developed countries.
In Canada, according to the Canadian Cancer Society Statistics-
2012, it is one of the leading causes of cancer related mortalities
[10]. Currently established markers are insufficient for accurate
prediction of prognosis in colorectal cancer patients. Therefore,
identification of new prognostic markers may assist improving the
prognostic models, which in turn may help improve the survival
outcomes of colorectal cancer patients. In this study, we
hypothesized that the genetic variations within the select genes
of the hypoxia pathway are associated with the risk of outcome in
colorectal cancer patients. To test our hypothesis, we conducted
this study in two phases: In phase I, we focused on three HIF-
coding genes (HIF1A, HIF1B, and HIF2A) and three genes
regulated under the hypoxic conditions (LOX,MIF, and CXCL12)
and investigated the relationship of their SNPs (n = 49) with
outcomes in a small cohort of colorectal cancer patients (n = 272).
In phase II, we focused on five HIF-coding genes (HIF1A,
HIF1B, HIF2A, HIF2B and HIF3A) and two hypoxia-inducible
genes (LOX and CXCL12) and investigated the relationship of
their SNPs (n = 77) with the risk of outcome in an additional
colorectal cancer patient cohort (n = 535).
Materials and Methods
This research project was carried out in two phases: phase I and
phase II. Phase II was initiated after the completion of phase I
when a large-scale genotype data for a larger patient cohort was
obtained by our group as part of another project. As illustrated in
Figure 1, there are differences between phase I and phase II in
terms of genes, SNPs and patient cohorts investigated.
Ethic statement
Requirement for patient consent was waived by the local REB
committee (Human Investigation Committee (HIC) of Memorial
University; recently renamed as The Health Research Ethics
Authority (HREA)) for the patients in phase I. Written consent was
obtained from either the patients or their family members (in case
of deceased patients) in the phase II cohort. During this study, all
patient-related data was investigated anonymously. This particular
study was also approved by HIC.
Study samples
a) Phase I cohort. The first cohort consisted of 280 patients
and was described in detail previously [11]. These patients were
diagnosed with colorectal cancer between 1997–1998 in the
Avalon Peninsula, Newfoundland. Patient in this cohort were
followed up till 2009. For this project, DNA samples from 272 of
the patients were available for the genotyping reactions.
b) Phase II cohort. The second cohort is a sub-cohort of the
patients recruited to the Newfoundland Colorectal Cancer
Registry (NFCCR). The NFCCR cohort was recruited between
1999 and 2003 and described in other publications [12,13]. In the
NFCCR cohort, there are 736 patients with stage I–IV tumors and
with clinicopathological and prognostic data collected till 2010
[11]. Among these patients, a total of 535 patients with available
genotypes obtained using the genomewide SNP genotyping
method (see below) were included in this phase of the project.
Selection of genes
a) Phase I. Six hypoxia pathway genes (HIF1A, HIF1B,
HIF2A, LOX, MIF and CXCL12) were selected.
b) Phase II. In phase II of this project, our primary aim was
to investigate the associations of polymorphisms from the selected
genes in phase I (HIF1A, HIF1B, HIF2A, LOX, MIF and
CXCL12) in a larger patient cohort. By taking advantage of the
availability of genotypes, we also aimed to include two additional
HIF-coding genes (HIF2B and HIF3A) in this phase.
Selection of SNPs
a) Phase I. In order to prevent redundancy in polymorphisms
investigated, we followed an approach that involved the calcula-
tion of correlation coefficients (r2) between the genotypes of
polymorphisms per gene; from those SNPs that were highly
correlated with each (r2$0.8), only one representative SNP was
included into the study.
For this purpose, for each gene included in this study the
genotype data for the Caucasian samples were downloaded from
the HapMap database [14] prior to start of the project, which
were used to construct linkage disequilibrium maps of the genes
using the Haploview software [15]. r2 values were calculated and
tagSNPs were determined using the pairwise tagger [16]
procedure implemented in Haploview. Both tagSNPs and SNPs
that are not tagged by the tagSNPs were aimed to be included to
have a comprehensive analysis of each gene. In phase I, total of 49
such SNPs were successfully genotyped using this approach
(Table S1 in File S1). Among the 49 SNPs, HIF2A rs2346175
polymorphism had .15% missing data and three polymorphisms
(HIF1B rs3738483, HIF2A rs6753127 and HIF2A rs11687512)
had minor allele frequencies (MAFs),10% in the phase I cohort.
b) Phase II. Eighty-one SNPs were selected from the eight
hypoxia pathway genes using the approach described in phase I.
From the selected SNPs, four SNPs that had a MAF,10% were
excluded from the statistical analysis (HIF1B rs10305724, HIF1B
rs3738483, HIF2B rs16972160, and HIF2B rs1139651), which
resulted in 77 SNPs to be included in this phase (Table S2 in File
S1). No polymorphism had more than 15% missing genotype
data. Genotypes of no SNP from the MIF gene was available for
this cohort. Thus, a total of 77 SNPs from seven genes (HIF1A,
HIF1B, HIF2A, HIF2B, HIF3A, LOX and CXCL12) were
included into phase II.
Thirteen SNPs were investigated in both patient cohorts. In
addition, there were 15 SNPs investigated in phase I that had
highly correlated genotypes with other SNPs investigated in the
phase II cohort (Table S3 in File S1): the remaining SNPs were
investigated in either cohort I or cohort II, but not in both. Since
SNPs with highly correlated genotypes can serve as surrogates for
each other, during this study we also checked (in addition to
identical SNPs) whether the results of the statistical tests obtained
for proxy SNPs in both cohorts were similar in terms of their
associations with the survival times.
Hypoxia Pathway Variants and Outcome in Colorectal Cancer
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Genotyping
a) Phase I. In this phase, DNA samples were extracted either
from blood samples or from non-tumor colorectal tissue blocks
obtained during surgery. The genotypes of the 49 polymorphisms
included in this phase of the study were obtained by either
Sequenom MassArray technology at an outsourcing genotyping
facility (University Health Network Analytical Genetics Technol-
ogy Centre, Canada; n= 35 SNPs) or in-house TaqMan SNP
genotyping assays (n = 14 SNPs). For both MassArray and
TaqMan SNP genotyping assays, at least 5% of the study subjects
were genotyped twice and all genotypes obtained were 100%
concordant. Each genotype reaction also contained non-template
controls to detect external DNA contamination. Those DNA
samples that were failed to be genotyped by TaqMan SNP
genotyping assays were attempted to be genotyped two or more
times depending on the availability of DNA samples.
TaqMan SNP genotyping
TaqMan SNP genotyping assays were performed in a 96 well
fast reaction plates using the ABI 7900HT Fast Real-Time PCR
System. Typically genotyping reactions contained 9 ml of reaction
mix and 1 ml of DNA sample (4 ng/ml). The reaction mix
consisted of 5 ml of TaqMan Universal PCR Master Mix (26)
(Applied Biosystems PN 4304437), 0.25 ml of SNP Genotyping
Assay Mix (206) (specific to each SNP) and 3.25 ml of sterile water.
In some cases, especially those that showed poor amplification, the
reaction volume was 5 ml (containing 4 ng DNA); this was done to
increase the DNA concentrations in reactions. The assay IDs for
the SNPs genotyped by this method are shown in Table S4 in
File S1. A pre-run scan was performed prior to start of
amplification. The PCR reaction conditions were as follow: a)
activation of AmpErase UNG at 50uC for 2 mins, b) AmpliTaq
Gold polymerase activation at 95uC for 10 mins, and c) 40 cycles
of denaturation of DNA at 95uC for 15 sec followed by primer
annealing and extension at 60uC for 1 min. After completion of
the reactions, a post-run scan was performed and the data was
analyzed using the sequence detection software (SDS). The SDS
genotyping results were also manually checked to call the final
genotypes by one of us (SS).
b) Phase II. In phase II of this project, the genotype data of
the 77 SNPs were obtained as a part of a whole genome SNP
genotyping study. Genotypes were obtained using the Illumina
Human Omni1-Quad Bead Chip at a service provider (Centrillion
Genomic Services, USA) using the DNA samples extracted from
the blood samples.
Statistical methods
Genotypes obtained were organised in Microsoft Excel sheets
and the statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS) software. Prior to statistical
analysis, all variables were checked for missing data. In addition,
MAFs of SNPs were calculated and genotypes were checked for
deviations from the Hardy Weinberg Equilibrium (HWE). HWE
was calculated using the Chi-square test. Variables that had more
than 15% missing data or deviating from the HWE were included
into the univariate analysis for exploratory purposes, but were
excluded from the multivariable analysis. Genotypes were coded
assuming the dominant genetic model. Except age, all other
variables included in the analysis were categorical; age was
analysed as a continuous variable.
Three different measures of outcome were used for the statistical
analysis: overall survival (OS), disease free survival (DFS) and
disease specific survival (DSS). For OS, death was the clinical end
point (defined as death by any cause). For DFS, occurrence of
recurrence of disease or metastasis or death was the clinical end
point. For DSS, colorectal cancer specific death was the clinical
Figure 1. SNP: single nucleotide polymorphism.
doi:10.1371/journal.pone.0113513.g001
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end point. DSS information was available only for phase I cohort.
Patients who did not experience the event of interest during the
follow up period were censored at the date of their last follow up.
Survival curves were generated by the Kaplan Meier method.
The relationship between each variable and the outcome measures
(OS, DFS, DSS) was analyzed individually using Cox regression
method in univariate analysis. The p-values, Hazard Ratios (HRs)
and the 95% Confidence Intervals (CIs) for the HRs were also
computed by the Cox regression method. Variables that were
statistically significant in the univariate analysis (p,0.05) were
included into the multivariable Cox regression models. The
patient characteristics between two study cohorts were compared
using the Chi-square test statistic for categorical variables and the
Mann-Whitney U test for the continuous variables. A p value less
than 0.05 was considered as statistically significant; as this was an
exploratory analysis no correction for multiple testing was
performed. All tests were double sided.
Results
Phase I
Baseline characteristics of the phase I cohort are shown in
Table 1. In this cohort (n = 280), the median age at diagnosis was
68.4 years (range: 25.3–91.6), the median OS and DSS follow up
time was 5.3 years (range: 0–12.5 years) and the median DFS
follow up time was 3.4 years (range: 0–12.5 years).
Out of 49 polymorphisms investigated in this phase, the
genotype frequencies for seven SNPs (LOX rs10040971, HIF1B
rs10847, CXCL12 rs2236534, CXCL12 rs2236533, CXCL12
rs11592974, HIF2A rs9973653 and HIF2A rs4145836) deviated
from HWE (Table S1 in File S1). These SNPs were included in
univariate analysis for exploratory purposes.
In univariate analysis for overall survival, three SNPs were
found to be significantly associated (p,0.05) with outcome: LOX
rs10519694 (p = 0.046; HR=0.735; 95% CI: 0.543–0.994),
HIF2A rs11125070 (p= 0.003; HR=0.616; 95% CI: 0.447–
0.848) and HIF2A rs1868084 (p = 0.024; HR=0.678; 95% CI:
0.483–0.950; Table S5 in File S1). However, in a multivariable
model, associations of none of these SNPs remained statistically
significant when adjusted for age, grade, stage and MSI status
(Table 2).
In univariate analysis for disease specific survival, association of
none of the SNPs were significant (Table S6 in File S1).
In univariate analysis for disease free survival, two SNPs (LOX
rs10519694; p= 0.012; HR=0.685; 95% CI: 0.510–0.919 and
HIF2A rs11125070; p = 0.003; HR=0.629; 95% CI: 0.461–
0.858) were associated (p,0.05) with the survival time (Table S7
in File S1). One of these SNPs (HIF2A rs11125070) remained
statistically significant in the multivariable analysis when adjusted
for LOX rs10519694 genotypes, age, grade, stage, and MSI status
(HR: 0.619, 95% CI: 0.446–0.859, p= 0.004; Table 3).
Phase II
After the completion of phase I, a more comprehensive study
(phase II) was performed by adding polymorphisms from two
more HIF-coding genes (HIF2B, HIF3A) and by investigating
their associations with OS and DFS in a second and larger patient
cohort.
Baseline characteristics of the phase II cohort are shown in
Table 4. In the phase II cohort (n = 535), the median age was
61.2 years (range: 20.7–75.0 years), the median OS time was 6.34
years (range: 0.38–10.88) and the median DFS time was 5.98 years
(range: 0.22–10.88).
Of 77 SNPs (Table S2 in File S1), genotype frequencies of
seven polymorphisms deviated from HWE (HIF2B rs8041826,
HIF2B rs7172914, HIF2B rs1020398, HIF2B rs4778600,
HIF2B rs8033706, HIF3A rs12461322 and HIF3A
rs11665853); these SNPs were included only in the univariate
analysis for exploratory purposes.
In this phase of the project, HIF2A rs4953352 (p = 0.012;
HR=1.596; 95% CI: 1.107–2.300) and HIF2B rs12593988
(p = 0.024; HR=0.690; 95% CI: 0.500–0.952) polymorphisms
were associated with the risk of death in the univariate analysis
(p,0.05) (Table S8 in File S1). In multivariable analysis,
associations ofHIF2A rs4953352 (p,0.001; HR=2.189; 95% CI:
1.468–3.265) and HIF2B rs12593988 (p = 0.009; HR=0.627;
95% CI: 0.442–0.890) with overall survival remained significant
when also adjusted for vascular invasion status, sex, stage and MSI
status (Table 5).
In univariate disease free survival analysis, HIF2A rs4953352
(p = 0.009; HR=1.574; 95% CI: 1.122–2.207), HIF2B
rs12593988 (p = 0.042; HR=0.736; 95% CI: 0.548–0.988), and
HIF2B rs8033706 (p = 0.023; HR=0.704; 95% CI: 0.521–0.953)
polymorphisms were associated with the risk of recurrence,
metastasis or death (p,0.05) (Table S9 in File S1). In
multivariable analysis, HIF2A rs4953352 (p,0.001; HR=1.965;
95% CI: 1.366–2.828) and HIF2B rs12593988 (p= 0.017;
HR=0.678; 95% CI: 0.493–0.931) remained significantly associ-
ated with DFS time when adjusted for sex, location, stage, vascular
invasion and MSI status (Table 6). Of note, since the genotype
frequencies of the HIF2B rs8033706 polymorphism deviated from
HWE, it was not included in this multivariable model.
SNPs investigated in both phase I and phase II cohorts
A total of 13 SNPs were investigated in both cohorts. In
addition, according to the HapMap data, there were 15
polymorphisms investigated in phase I, whose genotypes were
highly correlated (r2$0.8) with 15 other polymorphisms investi-
gated in phase II (Table S3 in File S1). We reasoned that the
SNPs with highly correlated genotypes can serve as surrogates for
each other. These proxy SNPs prompted us to check whether an
association of a polymorphism detected in one cohort was
replicated in the other cohort.
For the HIF2A rs11125070 polymorphism associated with
disease free survival in the phase I cohort, the HIF2A rs4953342
polymorphism investigated in the phase II cohort was a proxy (r2.
0.90). Our results showed that HIF2A rs4953342 was not
associated with DFS in the phase II cohort (Table S9 in File
S1). Additionally, for the HIF2A rs4953352 polymorphism that
was detected to be associated with both overall and disease free
survivals in the phase II cohort, there was a polymorphism
(HIF2A rs6706003) genotyped in phase I with highly correlated
genotypes (r2 = 0.87). Similarly, this polymorphism was not
detected to be associated with either OS (Table S5 in File S1)
or DFS (Table S7 in File S1) in the phase I cohort.
There was no proxy SNP studied in phase I cohort for the
HIF2B rs12593988 polymorphism that we detected as associated
with OS and DFS times in the patient cohort II.
Differences between the phase I and phase II cohorts in
terms of their clinicopathological features
Phase I and phase II cohorts significantly differed from each
other in terms of the following baseline characteristics: age: p,
0.001, sex: p = 0.037, grade: p,0.001, lymphatic invasion: p,
0.001, location: p,0.001 and stage: p = 0.018.
Hypoxia Pathway Variants and Outcome in Colorectal Cancer
PLOS ONE | www.plosone.org 4 November 2014 | Volume 9 | Issue 11 | e113513
Discussion
In this study, we aimed to investigate the associations of genetic
variations from select genes functioning in the hypoxia pathway
and clinical outcome in colorectal cancer patients. This study
involves two different cohorts and somehow overlapping yet not
identical sets of genes and SNPs as depicted in Figure 1.
Excluding the 13 SNPs that were common between phase I and II,
a total of 113 different SNPs were investigated in either phase I or
phase II.
In phase I of this project, 49 SNPs from six genes in hypoxia
pathway and their relation to outcome in the patient cohort was
analyzed using three different measures of outcome (OS, DFS and
DSS). Our results showed that there was no association of these
polymorphisms with OS or DSS in this cohort. However, one
Table 1. Baseline characteristics of the phase I cohort.
Variables n %
Sex
Male 150 53.6
Female 130 46.4
Age at diagnosis
Median 68.42 years (range:25.29–91.61)
Grade
Poorly differentiated/undifferentiated 42 15
Well/moderately differentiated 234 83.6
Unknown 4 1.4
Histology
Mucinous 43 15.4
Non-mucinous 237 84.6
Location
Rectum 57 20.4
Colon 223 79.6
Lymphatic invasion of tumor
Lymphatic invasion (+) 110 39.3
Lymphatic invasion (2) 70 25
Unknown 100 35.7
Stage
I 54 19.3
II 94 33.6
III 76 27.1
IV 47 16.8
Unknown 9 3.2
MSI status
MSI-H 34 12.1
MSS/MSI-L 246 87.9
Prognostic and follow up information
OS status at the time of last follow up
Dead 172 61.4
Alive 108 38.6
Median OS and DSS (follow up) time 5.31 years (range: 0–12.52)
DFS status at the time of last follow up
Recurrence/metastasis/death (+) 184 65.7
Recurrence/metastasis/death (2) 96 34.3
DFS (follow up) time 3.37 years (range: 0–12.52)
DSS status at the time of last follow up
Death from colorectal cancer 113 40.4
Death from other causes or alive 167 59.6
(+): present, (2): absent, DFS: disease free survival, DSS: disease specific survival, MSI-H: microsatellite instability-high, MSI-L: microsatellite instability-low, MSS:
microsatellite stable, OS: overall survival.
doi:10.1371/journal.pone.0113513.t001
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frequent SNP located in the mRNA coding region of HIF2A gene
(rs11125070, NM_001430.4:c.27-21086A.T; minor allele fre-
quency: 30.4% in phase I cohort) was associated with DFS in
multivariable analysis independent of other prognostic indicators.
Specifically, patients with the AT and TT genotypes (genotypes
containing the minor allele T) had ,0.4 times decreased risk of
recurrence, metastasis or death compared to the patients with the
AA genotype. However, when the association of a highly
correlated polymorphism investigated in phase II cohort (HIF2A
rs4953342) was tested in relation to disease free survival, this
association was not detected in the phase II cohort. Therefore,
while the differences between the two cohorts in terms of their
clinicopathological features may have contributed to this discrep-
ancy, considering the fact that no correction for multiple testing
was applied in this study, we assume that the association observed
in the phase I cohort was a false positive association.
In phase II of this project, out of the 77 SNPs investigated two
SNPs (HIF2B rs12593988 and HIF2A rs4953352) were associ-
ated with outcome in both OS and DFS multivariable analyses.
HIF2B rs12593988 (NM_014862.3:c.31+8939A.G) and HIF2A
rs4953352 (NM_001430.4:c.27-8490T.C) are both frequent
polymorphisms (minor allele frequencies 19% and 49%, respec-
tively). Currently their biological consequences are unknown,
however, a regulatory role of these variants in influencing the gene
expression or function cannot be ruled out. For HIF2A
rs4953352, another polymorphism with highly correlated geno-
types (HIF2A rs6706003) was not associated with either OS or
DFS in the phase I cohort. Non-replication of this association may
be attributed to the differences between the two cohorts or to the
small sample size of the phase I cohort which may lead to an
insufficient study power to detect this association. However, if a
correction for multiple testing procedure was applied, the observed
association would not remain significant. Thus, the most likely
explanation is that the association observed in the phase II cohort
was a false-positive association.
There was no proxy SNP for the HIF2B rs12593988 in our
cohort I dataset; hence we were not able to test its association with
disease outcomes in an independent cohort.
Presently, studies testing the associations of the polymorphisms
of the hypoxia genes with overall or disease free survivals in
colorectal cancer are quite rare. For example, according to the
dbCPCO database [17] and a literature search performed, as of
January 2014 only four studies looked at the polymorphisms from
the genes investigated in this study (HIF1A, ARNT/HIF1B, and
Table 2. Multivariable analysis results for overall survival (phase I; n = 234).
Variables p-value HR 95% CI (lower) 95% CI (upper)
LOX rs10519694 (CT+TT vs CC) 0.129 0.767 0.544 1.08
HIF2A rs11125070 (AT+TT vs AA) 0.282 0.801 0.535 1.2
HIF2A rs1868084 (GC+GG vs CC) 0.293 0.796 0.521 1.218
Age ,0.001 1.045 1.029 1.06
Grade (poorly differentiated/undifferentiated vs well/moderately
differentiated)
,0.001 2.594 1.669 4.03
Stage ,0.001
Stage (II vs I) 0.247 1.399 0.792 2.472
Stage (III vs I) 0.002 2.534 1.423 4.514
Stage (IV vs I) ,0.001 14.398 7.617 27.213
MSI status (MSI-H vs MSS/MSI-L) 0.002 0.285 0.131 0.62
CI: confidence interval, HR: hazard ratio, MSI-H: microsatellite instability-high, MSI-L: microsatellite instability-low, MSS: microsatellite stable. Significant associations (p,
0.05) are shown in bold.
doi:10.1371/journal.pone.0113513.t002
Table 3. Multivariable analysis results for disease free survival (phase I; n = 236).
Variables p-value HR 95% CI (lower) 95% CI (upper)
LOX rs10519694 (CT+TT vs CC) 0.113 0.767 0.552 1.065
HIF2A rs11125070 (AT+TT vs AA) 0.004 0.619 0.446 0.859
Age ,0.001 1.034 1.019 1.048
Grade (poorly differentiated/undifferentiated vs well/moderately
differentiated)
0.099 1.437 0.934 2.213
Stage ,0.001
Stage (II vs I) 0.112 1.553 0.903 2.673
Stage (III vs I) ,0.001 2.93 1.684 5.095
Stage (IV vs I) ,0.001 133.705 55.984 319.324
MSI status (MSI-H vs MSS/MSI-L) 0.013 0.4 0.194 0.825
CI: confidence interval, HR: hazard ratio, MSI-H: microsatellite instability-high, MSI-L: microsatellite instability-low, MSS: microsatellite stable, n: number of patients.
Significant associations (p,0.05) are shown in bold.
doi:10.1371/journal.pone.0113513.t003
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CXCL12). The only study studied the HIF1B rs2228099
(Val174Val G/C) polymorphism did not find an association of it
with overall survival in a patient cohort [18]. Additionally, two
polymorphisms from the HIF1A gene (rs11549465 Pro582Ser C/
T [18,19] and rs11549467 Ala588Thr G/A [19] were investigated
in relation to overall or disease free survivals in other cohorts:
however these studies did not find an association of these
polymorphisms with these outcomes in their patient cohorts.
Finally, one CXCL12 gene polymorphism, G/A in 39-UTR
(rs1801157 G801A), was examined in relation to disease free
survival in two published studies. While in one study this
polymorphism was not associated with disease free survival [20],
Table 4. Baseline characteristics of the phase II cohort.
Variables n %
Sex
Female 207 38.7
Male 328 61.3
Age at diagnosis
Median 61.23 years (range: 20.7–75)
Histology
Mucinous 61 11.4
Non-mucinous 474 88.6
Location
Colon 355 66.4
Rectum 180 33.6
Stage
I 97 18.1
II 207 38.7
III 178 33.3
IV 53 9.9
Grade
Well/moderately differentiated 492 92
Poorly differentiated/undifferentiated 39 7.3
Unknown 4 0.7
Vascular Invasion
Vascular Invasion (2) 325 60.7
Vascular Invasion (+) 171 32
Unknown 39 7.3
MSI status
MSI-H 58 10.84
MSS/MSI-L 455 85.05
Unknown 22 4.11
Prognostic and follow up information
OS status
Alive 352 65.8
Dead 182 34.02
Unknown 1 0.18
OS time (follow up time)
Median 6.34 years (range 0.38–10.88)
DFS status
Recurrence/metastasis/death (2) 321 60
Recurrence/metastasis/death (+) 213 39.8
Unknown 1 0.2
DFS time (follow up time)
Median 5.98 years (range: 0.22–10.88)
(+): present, (2): absent, DFS: disease free survival, MSI-H: microsatellite instability-high, MSI-L: microsatellite instability-low, MSS: microsatellite stable, OS: overall
survival.
doi:10.1371/journal.pone.0113513.t004
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in another study it was found to be associated with disease free
survival in both univariate and multivariable analyses only in the
patients without lymph node metastasis [21]. These literature
findings show the rarity of published research including the
polymorphisms from our list of genes. In addition, among these
previously investigated polymorphisms, only the HIF1B
rs2228099 polymorphism was investigated in our study (in both
phase I and II). This indicates that except one polymorphism
(HIF1B rs2228099), polymorphisms reported in this manuscript
are investigated for the first time in relation to survival outcomes in
colorectal cancer.
Our study has certain limitations and strengths. A) As this was
an exploratory analysis, in order to minimize the false negative
findings a correction for multiple testing was not performed. We
should note that none of the associations detected in this study
would remain significant after applying, for example, the
Bonferroni test for correction. B) The patient cohort studied in
phase I was characterized by a relatively small sample size
(n = 272) and the phase I and II cohorts differed significantly from
each other in terms of some baseline clinicopathological features.
In addition, phase II patient cohort was inclined towards earlier
stages and thus was not representative of the NFCCR cohort (data
not shown). However, to our knowledge the phase II cohort
(n = 535) is also one of the largest cohorts investigated in such a
study in colorectal cancer. C) This study was limited with eight
genes functioning in the hypoxia pathway (HIF1A, HIF1B,
HIF2A, HIF2B, and HIF3A, MIF, CXCL12, and LOX); many
other genes in this pathway were not investigated. D) Polymor-
phisms included in this study were selected based on the genotype
correlation data, reducing the redundancy in experiments and
statistical analysis, though we also acknowledge that possibly many
other polymorphisms in these genes were missed and are thus
candidates for further investigations.
In conclusion, this is a study that investigated a large number of
polymorphisms from the hypoxia pathway genes, the majority of
which were studied in relation to disease outcomes for the first
time in colorectal cancer. Our results suggest that the HIF2B
rs12593988 polymorphism may be associated with overall and
disease free survivals in colorectal cancer, however, because of the
large number of tests performed in this study, these associations
are likely to be false-positives. We nevertheless report these
associations for the researchers who may be interested in
Table 5. Multivariable analysis results for overall survival (phase II; n = 477).
95% CI for HR
Variables p-value HR (lower) (upper)
HIF2A rs4953352 (TC+CC vs TT) ,0.001 2.189 1.468 3.265
HIF2B rs12593988 (GA+AA vs GG) 0.009 0.627 0.442 0.890
Sex (male vs female) 0.116 1.310 0.936 1.834
Stage ,0.001
Stage (II vs I) 0.166 1.491 0.847 2.623
Stage (III vs I) 0.039 1.846 1.033 3.299
Stage (IV vs I) ,0.001 9.746 5.287 17.965
Vascular invasion (+ vs 2) 0.179 1.257 0.901 1.755
MSI status (MSI-H vs MSS/MSI-L) 0.002 0.270 0.118 0.616
(+): present, (2): absent, CI: confidence interval, HR: hazard ratio, MSI-H: microsatellite instability-high, MSI-L: microsatellite instability-low, MSS: microsatellite stable.
Significant associations (p,0.05) are shown in bold.
doi:10.1371/journal.pone.0113513.t005
Table 6. Multivariable analysis results for disease free survival (phase II, n = 476).
95% CI for HR
Variables p-value HR (lower) (upper)
HIF2A rs4953352 (TC+CC vs TT) ,0.001 1.965 1.366 2.828
HIF2B rs12593988 (GA+AA vs GG) 0.017 0.678 0.493 0.931
Sex (male vs female) 0.137 1.267 0.928 1.730
Location (rectum vs colon) 0.119 1.277 0.939 1.736
Stage ,0.001
Stage (II vs I) 0.231 1.352 0.825 2.214
Stage (III vs I) 0.030 1.755 1.057 2.914
Stage (IV vs I) ,0.001 5.599 3.189 9.831
Vascular invasion (+ vs 2) 0.261 1.196 0.876 1.633
MSI status (MSI-H vs MSS/MSI-L) 0.018 0.454 0.236 0.874
(+): present, (2): absent, CI: confidence interval, HR: hazard ratio, MSI-H: microsatellite instability-high, MSI-L: microsatellite instability-low, MSS: microsatellite stable.
Significant associations (p,0.05) are shown in bold.
doi:10.1371/journal.pone.0113513.t006
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investigating HIF2B rs12593988 in relation to outcome in their
future studies. Overall, our results point to no evidence of
associations of the polymorphisms with the disease outcomes
investigated in this study.
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